Comparing PPJ Enterprise (OTCMKTS:PPJE) & Standard BioTools (NASDAQ:LAB)

PPJ Enterprise (OTCMKTS:PPJE) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for PPJ Enterprise and Standard BioTools, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PPJ Enterprise	0	0	0	0	0.00
Standard BioTools	1	2	0	0	1.67

Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 43.77%. Given Standard BioTools’ stronger consensus rating and higher possible upside, analysts plainly believe Standard BioTools is more favorable than PPJ Enterprise.

Valuation and Earnings

This table compares PPJ Enterprise and Standard BioTools”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PPJ Enterprise	$670,000.00	1.33	$10,000.00	N/A	N/A
Standard BioTools	$85.33 million	4.23	-$74.90 million	($0.20)	-4.70

PPJ Enterprise has higher earnings, but lower revenue than Standard BioTools.

Profitability

This table compares PPJ Enterprise and Standard BioTools’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PPJ Enterprise	N/A	N/A	N/A
Standard BioTools	-59.39%	-11.20%	-8.54%

Volatility and Risk

PPJ Enterprise has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.

Insider & Institutional Ownership

53.7% of Standard BioTools shares are owned by institutional investors. 23.2% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Standard BioTools beats PPJ Enterprise on 7 of the 11 factors compared between the two stocks.

About PPJ Enterprise

PPJ Healthcare Enterprises, Inc., through its subsidiaries, provides automated healthcare reimbursement cycle, online health information digital-systems, and practice information management digital-system software to health care providers and general businesses worldwide. The company offers the Automated Biller, a medical billing system that allows physicians to bill their medical insurance claims at the point of service without data entry, coding, or billing personnel. It also provides billing, specialty medical billing, collection, and workers comp lien collection services for health care providers in the areas of pain management, anesthesia and surgery centers practices, and various specialties of medicine. The company was formerly known as PPJ Enterprise and changed its name to PPJ Healthcare Enterprises, Inc. in October 2014. PPJ Healthcare Enterprises, Inc. was founded in 2000 and is headquartered in Reno, Nevada.

About Standard BioTools

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.